Navigation Links
Dynogen Reports Positive Results in Phase 1B GERD Study

WALTHAM, Mass.--(BUSINESS WIRE)--Jun 7, 2007 - Dynogen Pharmaceuticals, Inc. reported positive results of its randomized, double-blind, placebo-controlled Phase 1b trial of DDP733 for gastroesophageal reflux disease (GERD). The study was designed to demonstrate proof-of-concept for DDP733 as a treatment for nocturnal GERD (NGERD). The 0.5 mg dose of DDP733 achieved statistical significance over placebo on the primary endpoint of reduction in the number of reflux events and was safe and well tolerated. Dynogen is planning to initiate a Phase 2 study of DDP733 in GERD patients in 2008.

DDP733 is an oral, partial agonist of the serotonin type 3 receptor (5-HT(3)), which Dynogen is developing for gastrointestinal conditions such as GERD and irritable bowel syndrome with constipation (IBS-c). In this translational medicine study, healthy volunteers were given a high fat meal to induce gastroesophageal reflux. Reflux events were measured by intraesophageal impedance (the electrical resistance that provides insight into the height and duration of a reflux episode).

"With this second set of positive proof-of-concept data for DDP733, following closely on the heels of our positive Phase 2 data for DDP733 in irritable bowel syndrome with constipation, we've unlocked the potential of this compound as a treatment for two distinct and underserved GI disorders," said Lee R. Brettman, M.D., Chief Executive Officer at Dynogen. "We estimate the peak sales for these indications to be in excess of a billion dollars each, reflecting the significant unmet medical need represented by these disorders. Dynogen has the opportunity to make a real difference in the quality of life of many patients suffering from these disorders."

"We designed this study with the dual goals of obtaining an indication of efficacy and establishing appropriate doses for our later-stage clinical study, and I am pleased to say we accomplished both
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Dynogens DDP733 Reduces Reflux in Phase 1b GERD Study
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Dynogen Reports Positive Results Phase GERD Study
(Date:5/22/2015)... , May 22, 2015 Electrophysiologist ... Institute recently traveled to Boston, MA ... at the 2015 Heart Rhythm Society conference. These ... to focus on the ideas, people and technology ... Convergent is a hybrid, minimally invasive cardiac operation ...
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage ... regeneration, today announced that J.J. Finkelstein , chief ... corporate overview at two upcoming investor conferences. ... th Annual Microcap Conference on Thursday May 28, ... at 11:00 am EDT.  A webcast will be available ...
(Date:5/22/2015)... , May 22, 2015  RegeneRx Biopharmaceuticals, Inc. ... a peer-reviewed publication of the results of the ... (RegeneRx,s preservative-free eye drops) for the treatment of ... environment (CAE ® ) model.  The exploratory study ... which were previously disseminated by the Company in ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
(Date:5/23/2015)... (PRWEB) May 23, 2015 Dr. David Benvenuti, ... has just posted a new article to his ... As Dr Benvenuti explained in the fascinating blog, ... plugs in their earlobes. , Known as “gauging,” the technique ... hole, which Dr. Benvenuti said will eventually stretch the holes ...
(Date:5/23/2015)... On Wednesday, May 20, 2015, CareFirst BlueCross ... the target of a sophisticated cyberattack,” and that it, ... Information Technology (IT) security efforts in the wake of ... notable attack on health insurers was reported in February ... largest health insurer, revealed that they had suffered a ...
(Date:5/23/2015)... 23, 2015 Manufacturers are now required to ... (HSPF) of 8.2. Experts in the field agree that the ... , The HSPF score is what miles per gallon is ... the unit. Although the minimum HSPF score has been raised ... an HSPF score north of 12. Indeed, the regulation was ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 Javon ... at the Sports Medicine and Rehabilitation Center, 557 N. ... program, Mondays, June 1-July 20, 5:30-6:30 pm. , The ... coach, and Laurie Finke, RN, BSN, who will offer ... education on nutrition, running mechanics and show selection and ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 Injury lawyer Steven ... has been passed by the Maryland legislature but which has ... Maryland General Assembly passed HB 449 with overwhelming ... has not signed it into law. This bill ensures that ... is growing that demonstrates the danger of fracking to our ...
Breaking Medicine News(10 mins):Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3
... admitted to a Colorado trauma center appeared to decrease ... report in the January issue of Archives of Surgery, ... are accredited through the American College of Surgeons, according ... based on factors such as surgeon and nurse availability, ...
... with untreatable lung disease , , MONDAY, Jan. ... the lung disease idiopathic pulmonary fibrosis (IPF) have a ... IPF is untreatable, and patients usually die within five ... smokers with IPF may live longer than former smokers, ...
... The Veterinary Division of,FLAVORx, Inc., which ... the nation,s largest compounding pharmacy, have,teamed up ... veterinarians to make pet,medications taste good. The ... add flavors to specially-formulated prescription,suspensions from Wedgewood ...
... A $7,000 grant,awarded by the Delta Dental Fund ... Ohio Dental Association members to Ohio,children for the sixth ... a,children,s access to dental care event in which dentists ... This,year,s event kicks off February 1, 2008, with many ...
... HALIFAX, Jan. 21 /PRNewswire/ - ImmunoVaccine Technologies Inc. ... $3 Million from,the Atlantic Canada Opportunities Agency (ACOA), ... enable IVT to undertake a $6,million project to ... ACOA recognize the market potential of our innovative ...
... EAST AURORA, N.Y., Jan. 21 Moog Inc. (NYSE:,MOG.A ... earnings for,the period ended December 29, 2007 on Friday ... host a conference call beginning,at 10:00 a.m. EST, which ... Chairman and CEO, and John Scannell, CFO, will host,the ...
Cached Medicine News:Health News:Change in trauma level designation associated with improved patient survival 2Health News:Smoking Worsens Prognosis for IPF Patients 2Health News:FLAVORx Teams up with Wedgewood Pharmacy to Make it Even Easier to Make Pet Medications Taste Good 2Health News:FLAVORx Teams up with Wedgewood Pharmacy to Make it Even Easier to Make Pet Medications Taste Good 3Health News:Delta Dental Financial Support Helps ODA Members Serve Children in Need 2Health News:ImmunoVaccine Technologies Receives $3 Million From ACOA 2
... dual wavelength (532 nm and 940 nm) ... laser solution. This solid-state laser quickly and ... acne vulgaris. VariLite offers the clinical versatility ... as deeper, larger vessels in a convenient, ...
... PREMIUM SURGICLIP™ clip applier consists of an applier ... 15 or 20 titanium clips. , ,The ... or other tubular structure. As the handles of ... closed around the vessel or structure. As the ...
The LIGACLIP ERCA Endoscopic Rotating Multiple Clip Applier is intended for use on tubular structures or vessels wherever a metal ligating clip is indicated. The tissue being ligated should be consis...
The Tissue Approximating Forceps are to aid in the approximating of the tissue edges....
Medicine Products: